Fig. 7

A combination of vitamin C and 5-azacytidine could be a potential remedy for insufficient epigenetic priming. A IC50 values were calculated using cell viability measured on day 5. *p < 0.05, **p < 0.01 and ***p < 0.001 (two-way ANOVA). B, STING expression levels were measured using western blotting. C, D GLUT3 expression levels were measured using RNA-sequencing data and western blotting, GLUT3 is encoded by the SLC2A3 gene. E GLUT3 expression levels were measured using western blotting of empty vector-expressing and SLC2A3-overexpressing OCI-LY1 cell lines, OE: overexpression. F IC50 values were calculated using cell viability measured on day 5. *p < 0.05, **p < 0.01 and ***p < 0.001 (two-way ANOVA). G STING expression levels were measured using western blotting. H–J Subcutaneous tumor sizes, xenograft tumor images, and tumor weights of xenografts from empty vector-expressing or SLC2A3-overexpressing OCI-LY1 tumor-bearing models are shown. *p < 0.05, **p < 0.01 and ***p < 0.001 (t test). AZA: 5-azacytidine, VC: vitamin C, OE: overexpression